Navigation Links
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Date:1/16/2008

dent of research in metabolic diseases since 2004. While at Roche she oversaw drug discovery programs in diabetes, dyslipidemia and obesity, including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company, which was acquired by Bristol-Myers in 2001, in a variety of positions, including executive director of neuroscience biology and executive director of CNS and obesity research.

"VIA's strategy of addressing significant unmet medical needs of patients with cardiovascular disease by targeting the root cause of vascular inflammation is innovative and has significant potential," said Dr. Taub. "I look forward to supporting the excellent clinical and development work that is taking place and ensuring additional clinical candidates are brought forward."

Before becoming a pharmaceutical executive, Dr. Taub served in a number of academic medicine and clinical research positions. She was a tenured professor of genetics and medicine at the University of Pennsylvania School of Medicine from 1997 to 2001, and she remains an adjunct professor. Earlier she was an assistant professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. She is the author of more than 120 research articles. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The comp
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
6. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014  Lisa Kulik saw fireworks for the first ... thanks to a groundbreaking retinal implant co-invented by ... at the University of Southern California (USC) Eye Institute. ... Ariz. resident who has retinitis pigmentosa, a ... On June 2, she became the first person west ...
(Date:8/27/2014)... 27, 2014 Guggenheim Securities, the investment banking ... the hiring of veteran equity analyst Charles "Tony" Butler ... Butler will focus on the biotech/biopharma sector. ... of experience and a broad network of relationships in ... Director and Head of Equities at Guggenheim Securities. "His ...
(Date:8/27/2014)... 2014 Research and Markets has ... Pulp & Paper Industry Report 2014" report to ... Pulp & Paper Industry Report 2014 is a professional ... global enzyme for pulp & paper industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... FREMONT, Calif., Dec. 14 Vermillion, Inc. (Pink Sheets: ... Wallen, Ph.D. Chief Scientific Officer, Senior Vice President, Research ... board of directors upon confirmation of Vermillion,s bankruptcy plan. ... and development experience in diagnostics and biotechnology," said Gail ...
... , , , NATICK, Mass., Dec. ... announced the completion of a public offering of $2 billion aggregate ... statement. The public offering consists of $850 million of 4.50 ... due January 2020 and $300 million of 7.375 percent notes due ...
... ... the delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield move from sheet ... , ... December 14, 2009 -- ThermoFab, a US-based thermoforming company, has completed the delivery of ...
Cached Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2
(Date:8/26/2014)... of harmful bacteria, biofilms make the treatment of ... biofilm pose a significant health risk due to ... biofilm-protected bacteria account for some 80 percent of ... to 1,000 times more resistant to antibiotics than ... have stumbled onto a magic bullet," said David ...
(Date:8/26/2014)... succeeded in obtaining an unprecedented view of a ... a range of neurological illnesses, including Alzheimer,s disease, ... associated with stroke. , The team of biologists ... Department of Energy,s Advanced Photon Source at Argonne ... the intact NMDA (N-methyl, D-aspartate) receptor should serve ...
(Date:8/26/2014)... endemic tree has for the last 31 years been incorrectly ... and small trees. A New Zealand botanist has completed a ... diversity behind what was long considered a single tree species. ... PhytoKeys . , Known to botanists as ... discoveries made in the north-western South Island of New Zealand ...
Breaking Biology News(10 mins):Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3
... life in higher animals, vitamin D, once linked to only ... as a major player in contributing to overall human health, ... on vitamin D. In a paper published in the ... Nutrition , Norman identifies vitamin D,s potential for contributions ...
... Carolina State University is leading to a new kind ... from freshwater ponds, instead of from the sea. ... crabs look and taste just like their ocean-raised brethren. ... at historic lows since 2000. Dr. Dave Eggleston, director ...
... develop sustainable energy systems while reducing the harmful ... phased out over the next century. This optimistic ... technologies such as biomimetics and Dye Sensitized solar ... or storing solar energy, and nanocatalysis develops efficient ...
Cached Biology News:Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 2Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist 3Turning freshwater farm ponds into crab farms 2Europe rallies behind nanotechnology to wean world from fossil fuels 2Europe rallies behind nanotechnology to wean world from fossil fuels 3Europe rallies behind nanotechnology to wean world from fossil fuels 4
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recombinant Porcine IL-1 alpha/IL-1F1, CF...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Biology Products: